CLDI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Calidi Biotherapeutics Inc (CLDI) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, weak financial performance, and no significant positive catalysts to justify immediate investment. While the RSI indicates the stock is oversold, the lack of strong trading signals, insider activity, or institutional interest suggests it is better to hold off on investing for now.
The MACD is slightly positive and expanding, indicating a potential for upward momentum. However, the RSI at 19.893 signals the stock is oversold. Moving averages are bearish, with SMA_200 > SMA_20 > SMA_5, and the stock is trading below key pivot levels (Pivot: 0.3, S1: 0.278). Overall, the technical indicators suggest a bearish trend.
The company has partnered with Avance Clinical to initiate clinical trials for its candidate CLD-401, targeting non-small cell lung cancer and other solid tumors. This partnership could expedite regulatory approval and clinical trials in Australia.
The stock has shown a -3.58% regular market change and a -0.58% pre-market change. Financial performance is weak, with negative net income and EPS. No significant insider or hedge fund activity has been observed, and the stock's chance of short-term price appreciation is low.
In 2025/Q3, the company reported no revenue growth (0% YoY), a net income of -$10.82 million (up 114.13% YoY but still negative), and a significant drop in EPS to -2.21 (-71.48% YoY). Gross margin remains at 0%. Overall, the financials indicate poor performance and no clear growth trajectory.
No analyst rating or price target data is available for this stock.
